Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia

Federal University of Rio Grande do Sul

Status and phase: Completed; Phase 2

Conditions: Schizophrenia

Treatments: Drug: resveratrol

Study type: Interventional

Funder types: Other

Identifiers

NCT02062190

RESV-110553

ufrgs110553 (Other Identifier)

Details and patient eligibility

About

Resveratrol supplementation may improve cardiovascular risk factors and cognitive parameters in patients with schizophrenia taking antipsychotics?

Full description

Randomized, double-blind, placebo-controlled trial comparing supplementation with resveratrol or placebo in patients diagnosed with schizophrenia.

Enrollment: 19 patients

Sex: Male

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Men 18-65 years old, diagnosed with schizophrenia according to DSM-IV and ICD-10, which are in clozapine medication for at least 6 months.

Exclusion criteria

Patients will be excluded from the study:

• Have a diagnosis of diabetes
• Use other antipsychotic drugs, clozapine beyond
• Using medicines for diabetes or dyslipidaemia
• Accept not participate in any stage of the research.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

19 participants in 2 patient groups, including a placebo group

resveratrol

Active Comparator group

Treatment:

Drug: resveratrol

corn starch

Placebo Comparator group

Description:

(10 patients) 100mg 2x/day 1 month

Treatment:

Drug: resveratrol